Annals of Geriatric Education and Medical Sciences


Melasma like hyperpigmentation on face: A rare side effect of imatinib


Full Text PDF Share on Facebook Share on Twitter


Author Details: Anusha Gupta,Sunil Kumar*,Saurav Chaturvedi,Apoorva Nirmal

Volume : 5

Issue : 2

Online ISSN : 2348-7240

Print ISSN : 2348-7348

Article First Page : 79

Article End Page : 80


Abstract

Imatinib mesylate is a cytotoxic agent that is used in chronic myeloid leukaemia. Common reported side effect is hypopigmentation; here we report a 48 year old female who developed hyperpigmentation as melasma on her face while taking imatinib mesylate in a dose of 400 mg daily for chronic myeloid leukaemia.

Keywords: Drug-induced pigmentation, Imatinib-mesylate, Melasma, Chronic myeloid leukemia.

Doi :-https://doi.org/10.18231/2348-7240.2018.0019